Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, General Counsel | April 01, 2021 | April 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date April 01, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,388 |
Ending reported balance
After 2021-04-01 transaction · row 25
25 source rows · reconciled sequenceRow 1 · 2021-04-01 · Exercise / conversion · Acquired 33,000 · Balance 148,842 Row 2 · 2021-04-01 · Sale · Disposed 2,010 · Balance 146,832 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 3 · 2021-04-01 · Sale · Disposed 8,266 · Balance 138,566 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 4 · 2021-04-01 · Sale · Disposed 3,233 · Balance 135,333 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 5 · 2021-04-01 · Sale · Disposed 3,234 · Balance 132,099 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 6 · 2021-04-01 · Sale · Disposed 1,067 · Balance 131,032 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 7 · 2021-04-01 · Exercise / conversion · Acquired 21,000 · Balance 152,032 Row 8 · 2021-04-01 · Sale · Disposed 1,256 · Balance 150,776 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 9 · 2021-04-01 · Sale · Disposed 4,818 · Balance 145,958 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 10 · 2021-04-01 · Sale · Disposed 2,728 · Balance 143,230 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 11 · 2021-04-01 · Sale · Disposed 1,724 · Balance 141,506 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 12 · 2021-04-01 · Sale · Disposed 963 · Balance 140,543 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 13 · 2021-04-01 · Exercise / conversion · Acquired 10,000 · Balance 150,543 Row 14 · 2021-04-01 · Sale · Disposed 700 · Balance 149,843 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 15 · 2021-04-01 · Sale · Disposed 2,644 · Balance 147,199 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 16 · 2021-04-01 · Sale · Disposed 951 · Balance 146,248 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 17 · 2021-04-01 · Sale · Disposed 1,049 · Balance 145,199 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 18 · 2021-04-01 · Sale · Disposed 123 · Balance 145,076 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Row 19 · 2021-04-01 · Exercise / conversion · Acquired 33,001 · Balance 178,077 Row 20 · 2021-04-01 · Sale · Disposed 1,965 · Balance 176,112 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 21 · 2021-04-01 · Sale · Disposed 6,768 · Balance 169,344 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 22 · 2021-04-01 · Sale · Disposed 3,361 · Balance 165,983 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 23 · 2021-04-01 · Sale · Disposed 2,258 · Balance 163,725 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 24 · 2021-04-01 · Sale · Disposed 1,213 · Balance 162,512 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price. Row 25 · 2021-04-01 · Sale · Disposed 124 · Balance 162,388 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2027-01-05 | Direct | 39,000 |
Reported balance
After 2021-04-01 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2021-04-01 · Exercise / conversion · Disposed 33,000 · Balance 39,000 F22: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2027-12-11 | Direct | 29,090 |
Reported balance
After 2021-04-01 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2021-04-01 · Exercise / conversion · Disposed 21,000 · Balance 29,090 F23: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.58 · Expires 2028-12-17 | Direct | 51,000 |
Reported balance
After 2021-04-01 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2021-04-01 · Exercise / conversion · Disposed 10,000 · Balance 51,000 F24: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.83 · Expires 2026-02-02 | Direct | 6,116 |
Reported balance
After 2021-04-01 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2021-04-01 · Exercise / conversion · Disposed 33,001 · Balance 6,116 F25: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 262,210 |
Reported balance
Holding disclosure · report date 2021-04-01 · row 26
Holding and transaction disclosures are not merged.
1 source rowRow 26 · Balance 262,210 F21: Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
F21: Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares.
F22: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021.
F23: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021.
F24: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021.
F25: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Jan 5, 2021 20:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit (performance-based) · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001712 · doc4.xml · derivative · entry 6 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · shares: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · derivative.exercise_date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · derivative.expiration_date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit (performance-based) · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001712 · doc4.xml · derivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires not disclosed F5 · derivative.exercise_price: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · shares: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · derivative.exercise_date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F5 · derivative.expiration_date: On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 9,583 | $0.00 Strike: $23.46 | $0.00 |
DisclosureSEC source: 0001209191-21-001712 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,583 Underlying: Common Stock · 9,583 shares Expires 2028-03-20 F4 · date: On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F4 · shares: On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F4 · derivative.exercise_date: On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F4 · derivative.expiration_date: On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001712 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 568 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-20-061650 · doc4.xml · derivative · entry 6 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 110,208 shares as of December 1, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 257 | $39.46 | $10,141.22 |
DisclosureSEC source: 0001209191-20-061650 · doc4.xml · nonDerivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,708 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.22 to $39.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,522 | $38.49 | $58,581.78 |
DisclosureSEC source: 0001209191-20-061650 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,965 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $39.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,585 | $37.73 | $59,802.05 |
DisclosureSEC source: 0001209191-20-061650 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,487 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $38.11, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 5,000 | $13.88 | $69,400.00 |
DisclosureSEC source: 0001209191-20-061650 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 848 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · derivative · entry 11 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,090 Underlying: Common Stock · 848 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 52,864 shares as of November 16, 2020. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 624 | $35.00 | $21,840.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 7 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,072 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 848 | $18.30 | $15,518.40 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 6 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 562 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · derivative · entry 10 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,938 Underlying: Common Stock · 562 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 52,864 shares as of November 16, 2020. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · derivative · entry 9 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 414 | $35.00 | $14,490.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,848 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 562 | $18.30 | $10,284.60 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,595 | $34.51 | $124,063.45 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.09 to $34.86, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,020 | $33.75 | $68,175.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,295 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.03, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-059272 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 16:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-20-057300 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 107,812 shares as of November 4, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 16:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,364 | $28.00 | $94,192.00 |
DisclosureSEC source: 0001209191-20-057300 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,315 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 16:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 5,000 | $13.88 | $69,400.00 |
DisclosureSEC source: 0001209191-20-057300 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · derivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 156 | $24.55 | $3,829.80 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,679 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,459 | $24.19 | $132,053.21 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,835 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.53 to $24.49, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 15, 2020 at each separate price. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,615 | $21.04 | $118,139.60 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,294 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,615 | $21.00 | $117,915.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,909 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,615 | $22.70 | $127,460.50 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,524 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 857 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,615 | $21.00 | $117,915.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,282 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · derivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,615 | $21.21 | $119,094.15 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,107 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F1 · balance_after: 262,210 of these shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 262,210 of these shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006976 · doc4.xml · derivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 16:25 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-18-063664 · doc4.xml · derivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: This option was granted on December 18, 2018 with respect to 71,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 15:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $22.78 | $0.00 |
DisclosureSEC source: 0001209191-18-005803 · doc4.xml · derivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: This option was granted on January 25, 2018 with respect to 25,000 shares of Common Stock, with 25% vesting on January 25, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:08 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-17-065664 · doc4.xml · derivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2027-12-11 F1 · derivative.exercise_date: This option was granted on December 12, 2017 with respect to 72,500 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 07:57 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,400 | $12.03 | $101,074.68 |
DisclosureSEC source: 0001209191-17-037514 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,994 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 to $12.04, inclusive. F2 · balance_after: Includes 594 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 20:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-17-003284 · doc4.xml · derivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 115,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.